Skip to main content
. 2018 Feb 23;62(3):e02297-17. doi: 10.1128/AAC.02297-17

FIG 3.

FIG 3

Mean (±SD) concentration-versus-time profiles of levonadifloxacin in plasma (unbound) (circles), epithelial lining fluid (ELF) (triangles), and alveolar macrophages (AM) (squares) 2, 4, 6, 8, and 12 h after the ninth oral dose of alalevonadifloxacin (1,000 mg every 12 h). The y axis is on the log scale.